NeuroSense Secures Key Japanese Patent for ALS Drug PrimeC, Extending IP Protection Through 2042
NRSN sits 26% above its 52-week low of $0.63.
Summary
NeuroSense Therapeutics secured a Japanese patent for its lead ALS drug candidate, PrimeC, extending intellectual property protection through 2042. This patent grant in a key pharmaceutical market strengthens the company's global IP portfolio for PrimeC, following similar grants in the U.S., Australia, and Brazil. While a positive step for long-term commercialization as the company prepares for Phase 3 trials, it comes amidst significant financial challenges, including a 'going concern' warning and Nasdaq compliance issues.
At the time of this announcement, NRSN was trading at $0.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.6M. The 52-week trading range was $0.63 to $2.60. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.